News

Axios on MSN12d
Vinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.
Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
FDA names Dr. Vinay Prasad as top vaccine official
In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...
BioPharma Dive12d
Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
Scripps News on MSN13d
Drug industry critic Vinay Prasad will lead FDA's vaccine oversight
Vinay Prasad will serve as director of the FDA's Center for Biologics Evaluation and Research, which oversees vaccine and ...
Hosted on MSN13d
US FDA names agency critic Vinay Prasad as top vaccine official
(Reuters) -The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA ...
STAT12d
New CBER Director Vinay Prasad praises evidence, FDA reviewers in first speech to staff
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
The Manhattan Mercury13d
Dr. Vinay Prasad to Head FDA Vaccine, Biologics Division
WEDNESDAY, May 7, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a ...
BioSpace6d
Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter
President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...
Hosted on MSN13d
FDA names oncologist Vinay Prasad as top vaccine official
The US Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized COVID-19 restrictions ...